Journal
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY
Volume 40, Issue 9, Pages 1223-1232Publisher
TAYLOR & FRANCIS LTD
DOI: 10.3109/03639045.2013.814061
Keywords
Acetazolamide; Draize's test; in situ gel; intraocular pressure; nanoparticles; nanoprecipitation; transcorneal; permeation
Categories
Ask authors/readers for more resources
The objective of research was to develop a novel pH-triggered polymeric nanoparticulate in situ gel (NP-ISG) for ophthalmic delivery of acetazolamide (ACZ) to enhance the conjunctival permeation and precorneal residence time of the formulation by overcoming the limitations of protective ocular barriers. Nanoparticles (NP1-NP12) were developed by nanoprecipitation method and evaluated for pharmacotechnical characteristics including transmission electron microscopy. The optimized formulation, NP10 was dispersed in carbopol 934 P to form nanoparticulate in situ gels (NP-ISG1-NP-ISG5). NP-ISG5 was selected as optimized formulation on the basis of gelation ability and residence time. Ex vivo transcorneal permeation study exhibited significantly higher ACZ permeation from NP-ISG5 (74.50 +/- 2.20 mg/cm(2)) and NP10 (93.5 +/- 2.25 mg/cm(2)) than eye drops (20.08 +/- 3.12 mg/cm(2)) and ACZ suspension (16.03 +/- 2.14). Modified Draize test with zero score indicated nonirritant property of NP-ISG5. Corneal toxicity study revealed no visual signs of tissue damage. Further, NP-ISG5 when tested for hypotensive effect on intraocular pressure (IOP) in rabbits revealed that NP-ISG5 caused significant decrease in IOP (p<0.05) in comparison to eye drops. Conclusively, NP-ISG5 may offer intensive management of glaucoma via higher permeation, prolonged precorneal residence time and sustained drug release along with higher in vitro efficacy, safety and patient compliance.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available